Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study

• Jong-Mi Seong ,

  Contributed equally to this work with: Jong-Mi Seong, Nam-Kyong Choi

  Affiliations Office of Drug Safety Information II, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea, Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

  ⨯
• Nam-Kyong Choi ,

  Contributed equally to this work with: Jong-Mi Seong, Nam-Kyong Choi

  Affiliations Division of Clinical Epidemiology, Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital, Seoul, Republic of Korea, Medical Research Center, Seoul National University, Seoul, Republic of Korea

  ⨯
• Ju-Young Shin,

  Affiliation Office of Drug Utilization Review, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea

  ⨯
• Yoosoo Chang,

  Affiliation Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea

  ⨯
• Ye-Jee Kim,

  Affiliation Office of Drug Safety Information I, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea

  ⨯
• Joongyub Lee,

  Affiliation Division of Clinical Epidemiology, Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital, Seoul, Republic of Korea

  ⨯
• Ju-Young Kim,

  Affiliation Department of Family Medicine, Seoul National University Bundang Hospital, Seoul, Republic of Korea

  ⨯
• Byung-Joo Park

  * E-mail: bjpark@snu.ac.kr

  Affiliations Office of Drug Safety Information II, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea, Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Office of Drug Utilization Review, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea, Office of Drug Safety Information I, Korea Institute of Drug Safety & Risk Management, Seoul, Republic of Korea

  ⨯